Jove
Visualize
Contact Us

Related Concept Videos

Narcolepsy01:07

Narcolepsy

247
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
247
Sleep-Wake Cycles01:24

Sleep-Wake Cycles

1.9K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and  rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.9K
Management of Insomnia01:19

Management of Insomnia

351
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
351
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

540
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
540
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

292
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
292
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

859
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
859

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel genes associated with hypocretin-producing neurons identified by human gene expression profiling.

Journal of neuroimmunology·2026
Same author

Cannabis Use in Central Disorders of Hypersomnolence in the Netherlands.

Medical cannabis and cannabinoids·2025
Same author

Synergistic Impact of Sleep Disturbance and Social Isolation in Adult but Not Adolescent Female Mice.

Journal of sleep research·2025
Same author

Probability estimation of narcolepsy type 1 in DTA mice using unlabeled EEG and EMG data.

Sleep advances : a journal of the Sleep Research Society·2025
Same author

CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice.

Basic & clinical pharmacology & toxicology·2024
Same author

Physiological and psychological stress reactivity in narcolepsy type 1.

Sleep·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Oct 23, 2025

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

2.6K

Emerging therapeutic targets for narcolepsy.

Marieke Vringer1,2, Birgitte Rahbek Kornum1

  • 1Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Expert Opinion on Therapeutic Targets
|August 17, 2021
PubMed
Summary

Emerging narcolepsy treatments focus on hypocretin (Hcrt) receptors and potential autoimmune targets to improve excessive daytime sleepiness (EDS) and other symptoms. Research shows promising results but requires further investigation into side effects and core pathophysiology.

Keywords:
Hypocretin/orexinhypocretin receptor agonistsimmunotherapiesnarcolepsystimulants

More Related Videos

Electrocorticographic Recording of Cerebral Cortex Areas Manipulated Using an Adeno-Associated Virus Targeting Cofilin in Mice
08:44

Electrocorticographic Recording of Cerebral Cortex Areas Manipulated Using an Adeno-Associated Virus Targeting Cofilin in Mice

Published on: February 21, 2021

4.5K
Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

10.0K

Related Experiment Videos

Last Updated: Oct 23, 2025

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

2.6K
Electrocorticographic Recording of Cerebral Cortex Areas Manipulated Using an Adeno-Associated Virus Targeting Cofilin in Mice
08:44

Electrocorticographic Recording of Cerebral Cortex Areas Manipulated Using an Adeno-Associated Virus Targeting Cofilin in Mice

Published on: February 21, 2021

4.5K
Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

10.0K

Area of Science:

  • Neurology
  • Sleep Medicine
  • Pharmacology

Background:

  • Narcolepsy types 1 and 2 (NT1, NT2) are chronic sleep disorders marked by excessive daytime sleepiness (EDS) and disrupted sleep-wake cycles.
  • While the exact cause is unknown, NT1 involves the hypocretin (Hcrt) system, and current treatments offer symptomatic relief for EDS and cataplexy, often with residual symptoms.

Purpose of the Study:

  • This review explores novel therapeutic targets for narcolepsy.
  • Focus areas include hypocretin (Hcrt) receptors, wake-promoting pathways, GABAergic mechanisms for sleep stabilization, and potential immunotherapies targeting the autoimmune basis of narcolepsy.

Main Methods:

  • A comprehensive literature search was conducted using PubMed and ClinicalTrials.gov.
  • The search covered studies published up to June 2021, focusing on emerging narcolepsy treatments.

Main Results:

  • Targeting Hcrt receptors shows promise for alleviating narcolepsy symptoms, with ongoing drug development yielding positive initial outcomes.
  • Potential side effects of Hcrt receptor-targeted treatments require careful evaluation, and their peripheral roles remain largely uncharacterized.

Conclusions:

  • Hcrt receptor-targeted therapies offer a promising avenue for narcolepsy symptom management.
  • Immunotherapies present a potential strategy to address the underlying autoimmune pathophysiology, but further research is essential to identify optimal targets.